Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8679034 | 0.80 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL14489954 | 0.79 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL17036729 | 0.77 | ALDH1A1 (0.32) | ALDH1A1MAPTLMNA | |
| SCHEMBL2422228 | 0.77 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16490062 | 0.77 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2630537 | 0.76 | HPGD (0.40) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL2197372 | 0.75 | FAAH (0.43) | HPGDKDM4E | |
| SCHEMBL25767732 | 0.75 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16490061 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL12959327 | 0.73 | KIF11 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | claimed |
| US-20140088121-A1 | HSP90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-03-27 | — | — | US | claimed |
| EP-2694505-A1 | HSP90 INHIBITORS | Sloan-kettering Institute For Cancer Research (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138894-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-10-11 | — | — | WO | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-5834404-A | Substituted bicycloheptanedione derivative and herbicide | NIPPON SODA CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0791572-A1 | SUBSTITUTED BICYCLOHEPTANEDIONE DERIVATIVE AND HERBICIDE | NIPPON SODA CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| EP-0467621-B1 | N-phenyl-N'-alkylsulfonylureas, process for their preparation and antitumor compositions containing them | LILLY CO ELI (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5254589-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5216026-A | Administering to the mammal N-1-butanesulfonamide derivatives and salts | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| WO-1993008161-A1 | SULFONYL UREA AND CARBAMATE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0467621-A1 | N-phenyl-N'-alkylsulfonylureas, process for their preparation and antitumor compositions containing them | ELI LILLY AND COMPANY (US) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | ALDH1A1 2900/4885NR3C2 4398/4885SMN1; SMN2 651/4885 |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | ALDH1A1 2177/4885NR3C2 30/4885SMN1; SMN2 4522/4885 |
| US-20140088121-A1 | HSP90 Inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | ALDH1A1 4100/4885NR3C2 1263/4885SMN1; SMN2 4272/4885 |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 1352/4885NR3C2 2182/4885SMN1; SMN2 4644/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | ALDH1A1 4061/4885NR3C2 1262/4885SMN1; SMN2 4275/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | ALDH1A1 3972/4885NR3C2 1223/4885SMN1; SMN2 3743/4885 |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | ALDH1A1 2190/4885NR3C2 33/4885SMN1; SMN2 4543/4885 |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | ALDH1A1 888/4885NR3C2 549/4885SMN1; SMN2 3123/4885 |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | MEN1, MCL1, XPOT | ALDH1A1 4310/4885NR3C2 3510/4885SMN1; SMN2 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.